Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide

Haematologica - Italy
doi 10.3324/haematol.11917
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Cryptic 5q Deletion in a Patient With Myelodysplastic Syndrome

British Journal of Haematology
Hematology
2017English

Lenalidomide in 5q Minus Myelodysplastic Syndrome: How Long Is Enough?

Annals of Hematology
MedicineHematology
2009English

Deletion 5q in Myelodysplastic Syndrome: A Paradigm for the Study of Hemizygous Deletions in Cancer

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Myelodysplastic Syndromes With a Deletion 5q Display a Characteristic Immunophenotypic Profile Suitable for Diagnostics and Response Monitoring

Haematologica
Hematology
2014English

Clonal Heterogeneity in the 5q- Syndrome: P53 Expressing Progenitors Prevail During Lenalidomide Treatment and Expand at Disease Progression

Haematologica
Hematology
2009English

Myeloid Leukemia With T(7;21)(p22;q22) and 5q Deletion

Oncology Reports
MedicineCancer ResearchOncology
2013English

Lenalidomide With or Without Erythropoietin in Transfusion-Dependent Erythropoiesis-Stimulating Agent-Refractory Lower-Risk MDS Without 5q Deletion

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2015English

A Critical Role for Phosphatase Haplodeficiency in the Selective Suppression of Deletion 5q MDS by Lenalidomide

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Blood Consult: Treating Del(5q) Myelodysplastic Syndromes

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy